Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS). In the randomized, double-blind, placebo-controlled core st...

Full description

Saved in:
Bibliographic Details
Published in:Neurology 2009-01, Vol.72 (1), p.73-79
Main Authors: O'Connor, P., Comi, G., Montalban, X., Antel, J., Radue, E. W., de Vera, A., Pohlmann, H., Kappos, L.
Format: Article
Language:English
Subjects:
Administration, Oral
Adolescent
Adult
Biological and medical sciences
Disability Evaluation
Double-Blind Method
Female
Fingolimod Hydrochloride
Humans
Immunosuppressive Agents - administration & dosage
Incidence
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Medical sciences
Middle Aged
Multiple Sclerosis - drug therapy
Multiple Sclerosis - mortality
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Propylene Glycols - administration & dosage
Respiratory Function Tests - methods
Severity of Illness Index
Sphingosine - administration & dosage
Sphingosine - analogs & derivatives
Time Factors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!